A New Type of Medicine: Biotherapeutics Usher in a New Era

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Pharma's Almanac

Digital Sampling

Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling

Jiwoon Kim; Neulbit Kim; Hyeonjung Park

Samsung Biologics

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac